Cefixime

As a representative variety of the third-generation oral cephalosporins, cefixime exerts antibacterial activity by inhibiting the synthesis of bacterial cell walls, and has a broad-spectrum antibacterial effect against both Gram-positive bacteria and Gram-negative bacteria, with strong stability and low incidence of adverse reactions. It is clinically mainly used for the treatment of multi-system infections caused by sensitive bacteria, including bronchitis, pneumonia, pyelonephritis, cystitis, gonococcal urethritis, cholecystitis, scarlet fever, otitis media, etc. Its applicable population covers adults and children over 6 months old, and it is a commonly used basic drug for the treatment of community-acquired infections.At present, the market size of domestic cefixime preparations exceeds RMB 6 billion, and it has firmly ranked among the top three in terms of market share among oral cephalosporin varieties. In recent years, with the release of demand from the primary medical market, its compound annual growth rate has remained at around 4%. In terms of the competitive landscape, domestic production of APIs and generic drugs has achieved independent controllability, and domestic preparations account for more than 95% of the overall market share. With the normalized advancement of centralized procurement, the prices of preparations have stabilized, and the purity of upstream APIs and the compliance of impurity control have become the core competitive factors of manufacturers, and the market demand for related impurity reference standards continues to rise.CATO can provide a complete set of impurity reference standards for cefixime API. All products meet the requirements of multiple regulatory standards such as the Chinese Pharmacopoeia and FDA. A large number of products are in stock and can be shipped immediately, which can provide stable and reliable material basis support for pharmaceutical enterprises in API quality research, consistency evaluation and daily production quality control.

目前国内头孢克肟制剂市场规模超过60亿元，在口服头孢类品种中市场份额稳居前三，近年来随着基层医疗市场需求释放，年复合增长率保持在4%左右。竞争格局方面，国内原料药及仿制药生产已实现自主可控，国产制剂占整体市场份额超95%；随着集采常态化推进，制剂价格趋于平稳，上游原料药的纯度、杂质控制合规性成为生产企业核心竞争要素，相关杂质标准品的市场需求持续攀升。

CATO/佳途科技可提供头孢克肟API全套杂质标准品，所有产品均符合中国药典、FDA等多重法规标准要求，大量现货可即时发货，能够为药企的原料药质量研究、一致性评价及日常生产质量控制提供稳定可靠的物质基础支撑。